Drug interactions

Drug Metabolism Reviews

Volumn 41, Issue 3, 2009, Pages 486-527

  Boobis, Alan ^a   Watelet, Jean Baptiste ^b   Whomsley, Rhys ^c   Benedetti, Margherita Strolin ^d   Demoly, Pascal ^e   Tipton, Keith ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Shire Pharmaceuticals   (United Kingdom)

^d UCB PHARMA   (Belgium)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Dietary amines; Drug diet interactions; Drug drug interactions; Enzyme induction; Enzyme inhibition; P450; Transporters

Indexed keywords

ASTEMIZOLE; CAFFEINE; CETIRIZINE; CHLORCYCLIZINE; CHLORPHENIRAMINE; CLEMASTINE; DEXAMETHASONE; EBASTINE; FLUVOXAMINE; FORMOTEROL; FURAFYLLINE; HYDROXYZINE; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; MONTELUKAST; OLOPATADINE; PROMETHAZINE; RIFAMPICIN; RITONAVIR; ROFECOXIB; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERFENADINE; THEOPHYLLINE; TRIPELENNAMINE; UNINDEXED DRUG; WARFARIN; ZAFIRLUKAST; ANTIALLERGIC AGENT; CARRIER PROTEIN; CYTOCHROME P450;

ALLERGIC RHINITIS; BIOTRANSFORMATION; COMPETITIVE INHIBITION; COMPUTER MODEL; CUSHING SYNDROME; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SPECIFICITY; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HEALTH CARE ORGANIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE TRANSPORT; NONHUMAN; QT PROLONGATION; QUANTITATIVE ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SEDATION; SIDE EFFECT; THREE DIMENSIONAL IMAGING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DIET; DOSE RESPONSE; DRUG COMBINATION; DRUG INTERACTION; METABOLISM;

ANIMALS; ANTI-ALLERGIC AGENTS; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FOOD-DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL;

EID: 73449094945     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.1080/10837450902891550     Document Type: Review

References (376)

1. Ahrens, F., Gabel, G., Gartz, B., Aschenbach, J.R. (2002). Release and permeation of histamine are afected by diamine oxydase in the pig large intestine. Infamm Res 51(Suppl):S83-S84.
2. Anderson, M.C., Hasan, F., McCrodden, J.M., Tipton, K.F. (1993). Monoamine oxidase inhibitors and the cheese efect. Neurochem Res 18:1145-1149. (Pubitemid 23306348)
3. Andrés, N., Lizcano, J.M., Rodríguez, M.J., Romera, M., Unzeta, M., Mahy, N. (2001). Tissue activity and cellular localization of human semicarbazide-sensitive amine oxidase. J Histochem Cytochem 49:209-217. (Pubitemid 32113383)
4. Arimoto, R. (2006). Computational models for predicting interactions with cytochrome P450 enzyme. Curr Top Med Chem 6:1609-1618.
5. Arinç, E., Arslan, S., Bozcaarmutlu, A., Adali, O. (2007). Efects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation ofcarcinogenic activity of N-nitrosodimethylamine in kidney and lung. Food Chem Toxicol 45:107-111.
6. Averill-Bates, D.A., Agostinelli, E., Przybytkowski, E., Mondovi, B. (1994). Aldehyde dehydrogenase and cytotoxicity of purifed bovine serum amine oxidase and spermine in Chinese hamster ovary cells. Biochem Cell Biol 72:36-42.
7. Averill-Bates, D.A., Ke, Q., Tanel, A., Roy, J., Fortier, G., Agostinelli, E. (2008). Mechanism of cell death induced by spermine and amine oxidase in mouse melanoma cells. Int J Oncol 32:79-88.
8. Bachmann, K., White, D., Jauregui, L., Schwartz, J.I., Agrawal, N.G., Mazenko, R., et al. (2003). An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 43:1082-1090.
9. Bachmann, K.A. (2006). Inhibition constants, inhibitor concentrations, and the prediction of inhibitory drug drug interactions: pitfalls, progress, and promise. Curr Drug Metab 7:1-14.
10. Bailey, D.G., Arnold, J.M.O., Munoz, C., Spence, J.D. (1993). Grapefruit juice-felodipine interaction: mechanism, predictability, and efect of naringin. Clin Pharmacol Ter 53:637-642.
11. Bailey, D.G., Dresser, G.K., Kreeft, J.H., Munoz, C., Freeman, D.J., Bend, J.R. (2000). Grapefruit-felodipine interaction: efect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ter 68:468-477.
12. Bailey, D.G., Dresser, G.K., Leake, B.F., Kim, R.B. (2007). Naringin is a major and selective clinical inhibitor of organic anion-trans-porting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ter 81:495-502.
13. Bain, M.A., Fornasini, G., Evans, A.M. (2005). Trimethylamine: metabolic, pharmacokinetic, and safety aspects. Curr Drug Metab 6:227-240.
14. Banfeld, C. (2001). Lack of drug interactions between desloratadine and other common medications. Allergy 56(Suppl 68):200 (No.636).
15. Banfeld, C., Gupta, S., Marino, M., Lim, J., Afrime, M. (2002a). Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 41:311-318.
16. Banfeld, C., Herron, J., Keung, A., Padhi, D., Afrime, M. (2002b). Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 41(Suppl 1):37-44.
17. Barbanoj, M.J., Garcia-Gea, C., Antonijoan, R., Izquierdo, I., Donado, E., Pérez, I., Solans, A., et al. (2006). Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine, and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol Clin Exp 21:13-26.
18. Bardocz, S., Grant, G., Brown, D.S., Pusztai, A. (1988). Putrescine as a source of instant energy in the small intestine of the rat. GUT 42:24-28.
19. Barr, J., Weir, A.J., Brendel, K., Sipes, I.G. (1991). Liver slices in dynamic organ culture. II. An in vitro cellular technique for the study of integrated drug metabolism using human tissue. Xenobiotica 21:341-350.
20. Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., et al. (2001). Efect of grapefruit juice on digoxin phar-macokinetics in humans. Clin Pharmacol Ter 70:311-316.
21. Bejinen, J.H., Schellens, H.M. (2004). Drug interactions in oncology. Te Lancet Oncol 5:489-496.
22. Belchi-Hernandez, J., Florido-Lopez, J.F., Estrada-Rodriguez, J.L., Martinez-Alzamora, F., Lopez-Serrano, C., Ojeda-Casas, J.A. (1993). Sulphite-induced urticaria. Ann Allergy 71:230-232.
23. Beyer, K., Morrow, E., Li, X.M., Bardina, L., Bannon, G.A., Burks, A.W., et al. (2001). Efects of cooking methods on peanut allergenicity. J Allergy Clin Immunol 107:1077-1081.
24. Bieganski, T., Kusche, J., Feussner, K.D., Hesterberg, R., Richter, H., Lorenz, W. (1980). Human intestinal diamine oxidase: substrate specifcity and comparative inhibitor study. Agents Actions 10:108-110.
25. Blackwell, B., Marley, E. (1969). Monoamine oxidase inhibition and intolerance to foodstufs. Bibl Nutr Dieta 11:96-110.
26. Boomsma, F., van Dijk, J., Bhaggoe, U.M., Bouhuizen, A.M., van den Meiracker, A.H. (2000). Variation in semicarbazide-sensitive amine oxidase activity in plasma and tissues of mammals. Comp Biochem Physiol C Toxicol Pharmacol 126:69-78.
27. Boot, J.D., De Haas, S.L., Van, Gerven, J.M., De Smet, M., Leathem, T., Wagner, J., et al. (2008). MK-0873, a PDE4 inhibitor, does not infuence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ter 21:573-577.
28. Bressler, R. (2006). Grapefruit juice and prescription drug interactions-exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 61:12-18.
29. Brigelius-Flohé, R., Müller, C., Menard, J., Florian, S., Schmehl, K., Wingler, K. (2001). Functions of GI-GPx: lessons from selenium-dependent expression and intracellular localization. Biofactors 14:101-106.
30. Brzezinska-Blaszczyk, E. (1992). Histamine secretion form human mesenteric and adenoidal mast cells. Arch Immunol Ter Exp (Warsz) 40:97-102.
31. Bueb, J.L., Mousli, M., Landry, Y. (1991). Molecular basis for cellular efects of naturally occurring polyamines. Agents Actions 33:84-87.
32. Burdychova, R., Komprda, T. (2007). Biogenic amine-forming microbial communities in cheese. FEMS Microbiol Lett 276:149-155.
33. Burke, W.J., Li, S.W., Chung, H.D., Ruggiero, D.A., Kristal, B.S., Johnson, E.M., et al. (2004). Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25:101-115.
34. Buu, N.T., Lussier, C. (1989). Consequences of monoamine oxidase inhibition: increased vesicular accumulation of dopamine and norepinephrine and increased metabolism by cate-chol-O-methyltransferase and phenolsulfotransferase. Prog Neuropsychopharmacol Biol Psychiatry 13:563-568.
35. Calcabrini, A., Arancia, G., Marra, M., Crateri, P., Befani, O., Martone, A., Agastinelli, E. (2002). Enzymatic oxidation products of spermine induce greater cytotoxic efects on human multidrug-resistant colon carcinoma cells (LoVo) than on their wild-type counterparts. Int J Cancer 99:43-52.
36. Carlson, D.B., Perdew, G.H. (2002). A dynamic role for the Ah receptor in cell signaling? Insights from a diverse group of Ah receptor interacting proteins. J Biochem Mol Toxicol 16:317-325.
37. Carroccio, A., Wu, D., Cederbaum, A.I. (1994). Ethanol increases content and activity of human cytochrome P4502E1 in a transduced HepG2 cell line. Biochem Biophys Res Commun 203:727-733.
38. Cashman, J.R., Zhang, J. (2006). Human favin-containing mono-oxygenases. Annu Rev Pharmacol Toxicol 46:65-100.
39. Castell, J.V., Jover, R., Martinez-Jimenez, C.P., Gomez-Lechon, M.J. (2006). Hepatocyte cell lines: their use, scope, and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183-212.
40. Cederbaum, A.I. (2006). CYP2E1-biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med 73:657-672.
41. 1-antagonists ebastine and loratadine in healthy subjects: phar-macokinetic and pharmacodynamic efects. Br J Clin Pharmacol 59:346-354.
42. Chan, W.K., Delucchi, A.B. (2000). Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103-3112.
43. Chang, S.C., Lin, C.W., Jiang, C.M., Chen, H.C., Shih, M.K., Chen, Y.Y., et al. (2009). Histamine production by bacilli bacteria, acetic bacteria, and yeast isolated from fruit wines. Food Sciences Technol 42:280-285.
44. Chang, T.K., Waxman, D.J. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51-73.
45. Chatterjee, U., Mondal, G., Chakraborti, P., Patra, H.K., Chatterjee, B.P. (2006). Changes in the allergenicity during diferent preparations of Pomfret, Hilsa, Bhetki, and mackerel fsh as illustrated by enzyme-linked immunosorbent assay and immunoblotting. Int Arch Allergy Immunol 141:1-10.
46. Chen, C. (2008). Physicochemical, pharmacological, and pharma-cokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 15:2173-2191.
47. Cheung, C., Ma, X., Krausz, K.W., Kimura, S., Feigenbaum, L., Dalton, T.P., et al. (2005). Diferential metabolism of 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18:1471-1478.
48. Chiba, M., Xu, X., Nishime, J.A., Balani, S.K., Lin, J.H. (1997). Hepatic microsomal metabolism of montelukast, a potent leukot-riene D4 receptor antagonist, in humans. Drug Metab Dispos 25:1022-1031.
49. Christian, K., Lang, M., Maurel, P., Rafalli-Mathieu, F. (2004). Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene. Mol Pharmacol 65:1405-1414.
50. Cliford, C.P., Adams, D.A., Murray, S., Taylor, G.W., Wilkins, M.R., Boobis, AR., et al. (1997). Te cardiac efects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52:311-315.
51. Cockroft, K.M., Meistrell, M., III, Zimmerman GA, Risucci, D., Bloom, O., Cerami, A., et al. (1996). Cerebroprotective efects of aminoguanidine in a rodent model of stroke. Stroke 27:1393-1398.
52. Cuthbert, M.F., Greenberg, M.P., Morley, S.W. (1969). Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J 15:404-406.
53. Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R., Kim, R.B. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
54. Da Prada, M., Zürcher, G, Würthrich, I., Haefely, W.E. (1988). On tyramine, food beverages, and the reversible MAO inhibitor moclobemide. J Neural Transm 26(Suppl):33-56.
55. Dale, H.D., Laidlaw, P.D. (1910). Te physiological action of pj-iminazolyl-ethylamine. J Physiol (Lond) 41:318-344.
56. Das, R., Kanungo, M.S. (1982). Activity and modulation of ornithine decarboxylase and concentrations of polyamines in various tissues of rats as a function of age. Exp Gerontol 17:95-103.
57. de Graaf, IA., Draaisma, A.L., Schoeman, O., Fahy, G.M., Groothuis, G.M., Koster, H.J. (2007). Cryopreservation of rat precision-cut liver and kidney slices by rapid freezing and vitrifcation. Cryobiology 54:1-12.
58. de Jonge, ME., Huitema, A.D., van Dam, S.M., Beijnen, J.H., Rodenhuis, S. (2005). Signifcant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 55:507-510. (Pubitemid 40568983)
59. De Kanter, R., De Jager, M.H., Draaisma, A.L., Jurva, J.U., Olinga, P., Meijer, D.K., et al. (2002). Drug-metabolizing activity of human and rat liver, lung, kidney, and intestine slices. Xenobiotica 32:349-362.
60. De Santi, C, Pietrabissa, A., Spisni, R., Mosca, F., Pacifci, G.M. (2000a). Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30:609-617. (Pubitemid 30449570)
61. De Santi, C, Pietrabissa, A., Spisni, R., Mosca, F., Pacifci, G.M. (2000b). Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural favonoids. Xenobiotica 30:857-866. (Pubitemid 30765220)
62. De Wachter, E., Malfroot, A., De Schutter, I., Vanbesien, J., De Schepper, J. (2003). Inhaled budesonide induced Cushing's syndrome in cystic fbrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2:72-75.
63. Deferme, S., Augustijns, P. (2003). Te efect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 55:153-162.
64. Degner, D., Grohmann, R., Kropp, S., Rüther, E., Bender, S., Engel, R.R., et al. (2004). Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 37(Suppl 1):S39-S45.
65. Dekhuijzen, P.N., Koopmans, P.P. (2002). Pharmacokinetic profle of zafrlukast. Clin Pharmacokinet 41:105-114.
66. Devereux, W., Wang, Y., Stewart, T.M., Hacker, A., Smith, R., Frydman, B., et al. (2003) Induction of the PAOh1/SMO polyamine oxidase by polyamine analogues in human lung carcinoma cells. Cancer Chemother Pharmacol 52:383-390.
67. Devillier, P., Roche, N., Faisy, C. (2008). Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine, and levocetirizine: a comparative review. Clin Pharmacokinet 47:217-230.
68. Dilger, K., Zheng, Z., Klotz, U. (1999). Lack of drug interaction between omeprazole, lansoprazole, pantoprazole, and theophylline. Br J Clin Pharmacol 48:438-444.
69. Dilger, K., Schwab, M., Fromm, M.F. (2004). Identifcation of budesonide and prednisone as substrates of the intestinal drug efux pump P-glycoprotein. Infamm Bowel Dis 10:578-583.
70. Dogan, A., Rao, A.M., Hatcher, J., Rao, V.L.R., Baskaya, M.K., Dempsey, R.J. (1999). Efects of MDL 72527, a specifc inhibitor of polyamine oxidase, on brain edema, ischemic injury volume, and tissue polyamine levels in rats after temporary middle cerebral artery occlusion. J Neurochem 72:765-770.
71. Donato, M.T., Castell, J.V. (2003). Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 42:153-178.
72. Donato, M.T., Lahoz, A., Castell, J.V., Gómez-Lechón, M.J. (2008). Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 9:1-11.
73. Dorhout, B., van Faassen, A., van Beusekom, C.M., Kingma, A.W., de Hoog, E., Nagel, G.T., et al. (1997). Oral administration of deuterium-labelled polyamines to sucking rat pups: luminal uptake, metabolic fate, and efects on gastrointestinal maturation. Br J Nutr 78:639-654.
74. Down, G., Siederer, S., Lim, S., Daley-Yates, P. (2006). Clinical pharmacology of cilomilast. Clin Pharmacokinet 45:217-233.
75. Dresser, G.K., Bailey, D.G., Leake, B.F., Schwarz, U.I., Dawson, P.A., Freeman, D.J., et al. (2002). Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ter 71:11-20
76. Dresser, G.K., Bailey, D.G. (2003). Te efects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest. 33(Suppl 2):10-16.
77. Dresser, G.K., Kim, R.B., Bailey, D.G. (2005). Efect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ter 77:170-177.
78. Duan, J.Z. (2007). Applications of population pharmacokinetics in current drug labeling. J Clin Pharmacy Ter 32:57-79.
79. Dufour, C., Dandrifosse, G., Forget, P., Vermesse, F., Romain, N., Lepoint, A. (1987). Spermine and spermidine induce intestinal maturation in the rat. Gastroenterology 95:112-116.
80. Dupont, H., Davies, D.S., Strolin, Benedetti M. (1987). Inhibition of cytochrome P-450 dependent oxidation reactions by MAO inhibitors in rat liver microsomes. Biochem Pharmacol 36:1651-1657.
81. Dürr, D., Stieger, B., Kullak-Ublick, G.A., Rentsch, K.M., Steinert, H.C., Meier, P.J., et al. (2000). St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ter 68:598-604.
82. Edmondson, D.E., Binda, C., Mattevi, A. (2007). Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys 464:269-276.
83. Edwards, D.J., Fitzsimmons, M.E., Schuetz, E., Yasuda, K., Ducharme, M.P., Warbasse, L.H., et al. (1999). 6′,7′-dihydroxybergamottin in grapefruit juice and Seville orange juice: efects on cyclosporin disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ter 65:237-244.
84. Edwards, R.J., Murray, B.P., Murray, S., Schulz, T., Neubert, D., Gant, T.W., et al. (1994). Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis 15:829-836.
85. Edwards, R.J., Price, R.J., Watts, P.S., Renwick, A.B., Tredger, J.M., Boobis, A.R., Lake, B.G. (2003). Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31:282-288.
86. Ek, M., Söderdahl, T., Küppers-Munther, B., Edsbagge, J., Andersson, T.B., Björquist, P., et al. (2007). Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 74:496-503. (Pubitemid 46970845)
87. Ekins, S., Erickson, J.A. (2002). A pharmacophore for human preg-nane X receptor ligands. Drug Metab Dispos 30:96-99.
88. Ekins, S., Chang, C., Mani, S., Krasowski, M.D., Reschly, E.J., Iyer, M., et al. (2007). Human pregnane X receptor antagonists and agonists defne molecular requirements for diferent binding sites. Mol Pharmacol 72:592-603.
89. Elmore, B.O., Bollinger, J.A., Dooley, D.M. (2002). Human kidney diamine oxidase: heterologous expression, purifcation, and characterization. J Biol Inorg Chem 7:565-579.
90. EMEA. (1995). Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95). Online at: www.emea.europa.eu/pdfs/human/ewp/056095en.pdf. Accessed 21 Jan 2009.
91. EMEA. (2008). Concept Paper/Recommendation on the Need for Revision of (CHMP) Note for Guidance on the Investigation of Drug Interactions (CPMP/EWP/560/95). Online at: www.emea. europa.eu/pdfs/human/ewp/29793108en.pdf.
92. Ernst, E. (2005). Te efcacy of herbal medicine-an overview. Fundam Clin Pharmacol. 19:405-409.
93. Faber, M.S., Jetter, A., Fuhr, U. (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125-134.
94. Fahmi, O.A., Boldt, S., Kish, M., Obach, R.S., Tremaine, L.M. (2008). Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 36:1971-1974.
95. Farid, N.A., Payne, C.D., Small, D.S., Winters, K.J., Ernest, C.S., 2nd, Brandt, J.T. et al. (2007). Cytochrome P450 3A inhibition by ketoconazole afects prasugrel and clopidogrel pharmacokinet-ics and pharmacodynamics diferently. Clin Pharmacol Ter 81:735-741.
96. Farkas, D., Greenblatt, D.J. (2008). Infuence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 4:381-393.
97. Favreau, L.V., Johnson, W.W., Chu, I., Soares, A., Clement, R.P., White, R.E. (2003). Desloratadine is not transported by human organic anion transport polypeptide-A. European Academy of Allergology and Clinical Immunology (EAACI), abstract book:278-279 (No.966).
98. FDA. (1997). Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro. Online at: www. fda.gov/cder/guidance/clin3.pdf (April 1997).
99. FDA. (1999). Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Online at: www.fda.gov/cber/gdlns/metabol.pdf (Nov 1999). Accessed 21 Jan 2009.
100. FDA. (2006). Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Online at: www.fda.gov/cber/gdlns/interactstud. pdf (9/11/2006).
101. Felton, J.S., Knize, M.G., Bennett, L.M., Malfatti, M.A., Colvin, M.E., Kulp, K.S. (2004). Impact of environmental exposures on the mutagenicity/ carcinogenicity of heterocyclic amines. Toxicology 198:135-145.
102. Fisher, M.M., Munro, I. (1983). Life-threatening anaphylactoid reactions to muscle relaxants. Anesth Analg 62:559-564.
103. Florang, V.R., Rees, J.N., Brogden, N.K., Anderson, D.G., Hurley, T.D., Doorn, J.A. (2007). Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology 28:76-82.
104. Fogel, W.A., Lewinski, A., Jochem, J. (2007). Histamine in food: is there anything to worry about? Biochem Soc Trans 35:349-352.
105. Foisy, M.M., Yakiwchuk, E.M., Chiu, I., Singh, A.E. (2008). Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and futicasone: a review of the literature. HIV Med 9:389-396.
106. Fowler, S., Zhang, H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. AAPS J 10:410-424
107. Fuhr, U., Klittich, K., Staib, A.H. (1993). Inhibitory efect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of cafeine in man. Br J Clin Pharmacol 35:431-436.
108. Geha, R., Buckley, C.E., Greenberger, P., Patterson, R., Polmar, S., Saxon, A., et al. (1993). Aspartame is no more likely than placebo to cause urticaria/angioedema: results of a multicenter, randomized, double-blind, placebo-controlled, crossover study. J Allergy Clin Immunol 92:512-520.
109. Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587.
110. 1-receptor antihistamine ebastine: a pilot study. Br J Clin Pharmacol 62:177-186.
111. Gómez-Lechón, M.J., Donato, T., Jover, R., Rodriguez, C., Ponsoda, X., Glaise, D., et al. (2001). Expression and induction of a large set of drug-metabolizing enzymes by the highly diferentiated human hepatoma cell line BC2. Eur J Biochem 268:1448-11159
112. Goodman, D.L., McDonnell, J.T., Nelson, H.S., Vaughan, T.R., Weber, R.W. (1990). Chronic urticaria exacerbated by the anti-oxidant food preservatives, butylated hydroxyanizole (BHA), and butylated hydroxytoluene (BHT). J Allergy Clin Immunol 86:570-575.
113. Gorski, P. (1985). Polymyxin B-induced basophil degranulation in atopic and nonatopic asthmatic patients. Allergol Immunopathol (Madrid) 13:379-382. (Pubitemid 16244500)
114. Gorski, P., Rozniecki, J., Kuzminska, B., Grzegorczyk, J. (1985). Bronchial and basophil reaction to polymyxin B in asthmatic patients. Allergy 40:70-72. (Pubitemid 15167271)
115. Gozalo Reques, F., Estrada Rodriguez, J.L. (1999). Tolerability of leu-kotriene modifers in asthma: a review of clinical experience. BioDrugs 11:385-394.
116. Graham, M.J., Lake, B.G. (2008). Induction of drug metabolism: species diferences and toxicological relevance. Toxicology 254:184-191.
117. Granneman, G.R., Braeckman, R.A., Locke, C.S., Cavanaugh, J.H., Dubé, L.M., Awni, W.M. (1995). Efect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 29 (Suppl 2):77-83.
118. Greco, W.R., Bravo, G., Parsons, J.C. (1995). Te search for synergy: a critical review from a resonse surface perspective. Pharmacol Rev 47:331-385.
119. Gross-Steinmeyer, K., Stapleton, P.L., Tracy, J.H., Bammler, T.K., Lehman, T., Strom, S.C., et al. (2005). Infuence of Matrigel-overlay on constitutive and inducible expression of nine genes encoding drug-metabolizing enzymes in primary human hepa-tocytes. Xenobiotica 35:419-438.
120. Grover, G.S., Brayman, T.G., Voorman, R.L., Ware, J.A. (2007). Development of in vitro methods to predict induction of CYP1A2 and CYP3A4 in humans. Assay Drug Dev Technol 5:793-804.
121. Gueant, J.L., Aimone-Gastin, I., Namour, F., Laroche, D., Bellou, A., Laxenaire, M.C. (1998). Diagnosis and pathogenesis of the ana-phylactic and anaphylactoid reactions to anaesthetics. Clin Exp Allergy 28(Suppl 4):65-70.
122. Guo, L.Q., Fukuda, K., Ohta, T., Yamazoe, Y. (2000). Role of furano-coumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766-771.
123. Gupta, S., Banfeld, C., Kantesaria, B., Marino, M., Clement, R., Afrime, M., et al. (2001). Pharmacokinetic and safety profle of desloratadine and fexofenadine when coadministered with azi-thromycin: a randomized, placebo-controlled, parallel-group study. Clin Ter 23:451-466.
124. 1-receptor antagonists. Drug Metab Dispos 26:536-539.
125. Hamelin, B.A., Bouayad, A., Méthot, J., Jobin, J., Desgagnés, P., Poirier, P., et al. (2000). Signifcant interaction between the non-prescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ter 67:466-477.
126. Hariparsad, N., Carr, B.A., Evers, R., Chu, X. (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36:1046-1055.
127. Hart, S.N., Zhong, X.B. (2008). P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4:439-452.
128. Hasan, F., McCrodden, J.M., Kennedy, N.P., Tipton, K.F. (1988). Te involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm (Suppl) 26:1-9.
129. Hayashi, S., Murakami, Y., Matsufuji, S. (1996). Ornithine decar-boxylase antizyme: a novel type of regulatory protein. Trends Biochem Sci 21:27-30.
130. Hermann, R., Siegmund, W., Giessmann, T., Westphal, K., Weinbrenner, A., Hauns, B., et al. (2007). Te oral, once-daily phosphodiesterase 4 inhibitor rofumilast lacks relevant phar-macokinetic interactions with inhaled budesonide. J Clin Pharmacol 47:1005-1013.
131. Hernandez, M., Solé, M., Boada, M., Unzeta, M. (2006). Soluble semicarbazide sensitive amine oxidase (SSAO) catalysis induces apoptosis in vascular smooth muscle cells. Biochim Biophys Acta 1763:164-173.
132. Hiroi, T., Imaoka, S., Funae, Y. (1998). Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249:838-843.
133. Holtbecker, N., Fromm, M.F., Kroemer, H.K., Ohnhaus, E.E., Heidemann, H. (1996). Te nifedipine-rifampin interaction: evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
134. Honig, P.K., Wortham, D.C., Hull, R., Zamani, K., Smith, J.E., Cantilena, L.R. (1993). Itraconazole afects single-dose terfenadine phar-macokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 33:1201-1206.
135. Honig, P.K., Wortham, D.C., Lazarev, A., Cantilena, L.R. (1996). Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfena-dine. J Clin Pharmacol 36:345-351. (Pubitemid 26123376)
136. Horinouchi, Y., Abe, K., Kubo, K., Oka, M. (1993). Mechanisms of vancomycin-induced histamine release from rat peritoneal mast cells. Agents Actions 40:28-36.
137. Horton, J.R., Sawada, K., Nishibori, M., Cheng, X. (2005). Structural basis for inhibition of histamine N-methyltransferase by diverse drugs. J Mol Biol 353:334-344.
138. Ingelman-Sundberg, M., Sim, S.C., Gomez, A., Rodriguez-Antona, C. (2007). Infuence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic, and clinical aspects. Pharmacol Ter 11:496-526.
139. Ioannides, C. (2002). Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478.
140. Ionescu, G., Kiehl, R. (1988). Monoamine and diamine oxidase activities in atopic eczema. Allergy 43:318-319.
141. Izquierdo-Pulido, M. (1996). Biogenic amines in European beers. J Agric Food Chem 44:33159-33163.
142. Izzo, A.A. (2004). Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19:1-16.
143. Jaakkola, T., Backman, J.T., Neuvonen, M., Niemi, M., Neuvonen, P.J. (2006). Montelukast and zafrlukast do not afect the phar-macokinetics of the CYP2C8 substrate pioglitazone. Eur J Clin Pharmacol., 62:503-509.
144. Jacobs, M.N., Dickins, M., Lewis, D.F. (2003). Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hER-beta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR), and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome pro-liferator activated receptor alpha (PPARalpha) ligand-binding domain from the human PPARgamma crystal structure. J Steroid Biochem Mol Biol 84:117-132.
145. Jänne, J., Raina, A., Siimes, M. (1964). Spermidine and spermine in rat tissues at diferent ages. Acta Physiol Scand 62:352-358.
146. Johnson, S.R., Marion, A.A., Vrchoticky, T., Emmanuel, P.J., Lujan-Zilbermann, J. (2006). Cushing's syndrome with secondary adrenal insufciency from concomitant therapy with ritonavir and futicasone. J Pediatr 148:386-388.
147. Johnson, W.W. (2008). Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance. Drug Metab Rev 40:101-147.
148. Jonsson, G., Astrom, A., Andersson. (1995). Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos 23:137-142
149. Kajita, J., Inano, K., Fuse, E., Kuwabara, T., Kobayashi, H. (2002). Efects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab Dispos 30:1504-1511.
150. Kameoka, S.M., Leavitt, P.M., Chang, C., Kuo, S.M. (1999). Expression of antioxidant proteins in human intestinal Caco-2 cells treated with dietary favonoids. Cancer Lett 146:161-167.
151. Kane, G.C., Lipsky, J.J. (2000). Drug-grapefruit juice interactions. Mayo Clin Proc 75:933-942.
152. Kanebratt, K.P., Andersson, T.B. (2008). HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 36:1137-1145.
153. Karjalainen, M.J., Neuvonen, P.J., Backman, J.T. (2006). Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab Dispos 34:2091-2096.
154. Kassahun, K., Skordos, K., McIntosh, I., Slaughter, D., Doss, G.A., Baillie, T.A., et al. (2005). Zafirlukast metabolism by cyto-chrome P450 3A4 produces an electrophilic alpha,beta-un-saturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol 18:1427-1437.
155. Katragadda, S., Budda, B., Anand, B.S., Mitra, A.K. (2005). Role of efux pumps and metabolizing enzymes in drug delivery. Expert Opin Drug Deliv 2:683-705.
156. Kawajiri, K., Fujii-Kuriyama, Y. (2007). Cytochrome P450 gene regulation and physiological functions mediated by the aryl hydrocarbon receptor. Arch Biochem Biophys 464:207-212.
157. Kawana, K., Ikuta, T., Kobayashi, Y., Gotoh, O., Takeda, K., Kawajiri, K. (2003). Molecular mechanism of nuclear trans-location of an orphan nuclear receptor, SXR. Mol Pharmacol 63:524-531.
158. Kennedy, M.J., Loehle, J.A., Grifn, A.R., Doll, M.A., Kearns, G.L., Sullivan, J.E., et al. (2008). Association of the histamine N-methyltransferase C314T (Tr105Ile) polymorphism with atopic dermatitis in Caucasian children. Pharmacotherapy 8:1495-1501.
159. Kenny, J.R., Chen, L., McGinnity, D.F., Grime, K., Shakeshef, K.M., Tomson, B., et al. (2008). Efcient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 38:1500-1517.
160. Kent, U.M., Aviram, M., Rosenblat, M., Hollenberg, P.F. (2002). Te licorice root derived isofavan glabridin inhibits the activities of human
161. Kiehl, R., Ionescu, G. (1989). [Histamine-degrading enzymes in atopic eczema]. Z Hautkr 64:1121-1123.
162. Koarai, A., Ichinose, M., Ishigaki-Suzuki, S., Yamagata, S., Sugiura, H., Sakurai, E., et al. (2003). Disruption of L-histidine decarboxylase reduces airway eosinophilia but not hyperresponsiveness. Am J Respir Crit Care Med 167:758-763.
163. Kobayash, K., Sueyoshi, T., Inoue, K., Moore, R., Negishi, M. (2003). Cytoplasmic accumulation of the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Mol Pharmacol 64:1069-1075.
164. Kosoglu, T., Meyer, I., Veltri, E.P., Statkevich, P., Yang, B., Zhu, Y., et al. (2002). Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simv-astatin. Br J Clin Pharmacol 54:309-319. (Pubitemid 35056576)
165. Koyano, S., Kurose, K., Saito, Y., Ozawa, S., Hasegawa, R., Komamura, K., et al. (2004). Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 32:149-154.
166. Krueger, S.K., Williams, D.E. (2005). Mammalian favin-containing mono-oxygenases: structure/function, genetic polymorphisms, and role in drug metabolism. Pharmacol Ter 106:357-387.
167. Kuefner, M.A., Schwelberger, H.G., Hahn, E.G., Raithel, M. (2008). Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma. Dig Dis Sci 53:436-442.
168. Kulczycki, A., Jr. (1986). Aspartame-induced urticaria. Ann Intern Med 104:207-208.
169. Kunduzova, O.R., Bianchi, P., Parini, A., Cambon, C. (2002). Hydrogen peroxide production by monoamine oxidase during ischemia/reperfusion. Eur J Pharmacol 448:225-230.
170. Kuramasu, A., Saito, H., Suzuki, S., Watanabe, T., Ohtsu, H. (1998). Mast cell-/basophil-specifc transcriptional regulation of human L-histidine decarboxylase gene by CpG methylation in the promoter region. J Biol Chem 273:31607-31614.
171. Lahu, G., Huennemeyer, A., von Richter, O., Hermann, R., Herzog, R., McCracken, N., et al. (2008). Efect of single and repeated doses of ketoconazole on the pharmacokinetics of rofumilast and rof-lumilast N-oxide. J Clin Pharmacol 48:1339-1349.
172. Larqué, E., Sabater-Molina, M., Zamora, S. (2007). Biological signif-cance of dietary polyamines. Nutrition 23:87-95.
173. Lee, C.R., Trasher, K.A. (2001). Difculties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 21:1240-1246.
174. Lee, Y.S., Lorenzo, B.J., Koufs, T., Reidenberg, M.M. (1996). Grapefruit juice and its favonoids inhibit 11fj-hydroxysteroid dehydrogenase. Clin Pharmacol Ter 59:62-71.
175. Lerche-Langrand, C, Toutain, H.J. (2000). Precision-cut liver slices: characteristics and use for in vitro pharmaco-toxicology. Toxicology 153:221-253.
176. Levy, J.H., Adelson, D., Walker, B. (1991). Wheal and fare responses to muscle relaxants in humans. Agents Actions 34:302-308.
177. Lewis, D.F., Ito, Y. (2008). Human cytochromes P450 in the metabolism of drugs: new molecular models of enzyme-substrate interactions. Expert Opin Drug Metab Toxicol 4:1181-1186.
178. Lewis, D.F., Ito, Y., Goldfarb, P.S. (2006). Structural modelling of the human drug-metabolizing cytochromes P450. Curr Med Chem 13:2645-2652.
179. Lewis, D.F., Lake, B.G., Dickins, M. (2007). Quantitative structure-activity relationships (QSARs) in inhibitors of various cytochromes P450: the importance of compound lipophilicity. J Enzyme Inhib Med Chem 22:1-6.
180. Li, P., Callery, P.S., Gan, L-S., Balani, S.K. (2007a). Esterase inhibition attribute of grapefruit juice leading to a new drug interaction. Drug Metab Dispos 35:1023-1031. (Pubitemid 46956420)
181. Li, P., Callery, P.S., Gan, L-S., Balani, S.K. (2007b). Esterase inhibition by grapefruit juice favonoids leading to a new drug interaction. Drug Metab Dispos 35:1203-1208. (Pubitemid 46956443)
182. Li, W., Yuan, X.M., Ivanova, S., Tracey, K.J., Eaton, J.W., Brunk, U.T. (2003). 3-aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem J 371:429-436.
183. Lijinsky, W. (1999) N-nitroso compounds in the diet. Mutat Res 443:129-138.
184. Lin, J.H. (2006). CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 23:1089-1116.
185. Lin, J., Cashman, J.R. (1997). Detoxication of tyramine by the favin-containing mono-oxygenase: stereoselective formation of the transoxime. Chem Res Toxicol 10:842-852.
186. Liu, K.H., Kim, M.G., Lee, D.J., Yoon, Y.J., Kim, M.J., Shon, J.H., et al. (2006). Characterization of ebastine, hydroxyebastine, and care-bastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793-1797.
187. Lizcano, J.M., Tipton, K.F., Unzeta, M. (1998). Purifcation and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J 331:69-78.
188. Lorenz, W., Ton, K., Barth, H., Neugebauer, E., Reimann, H.J., Kusche, J. (1983). Metabolism and function of gastric histamine in health and disease. J Clin Gastroenterol Suppl 1: 37-56.
189. Lortie, M.J., Novotny, W.F., Peterson, O.W., Vallon, V, Malvey, K., Mendonca, M., et al. (1996). Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional efects in the kidney of the rat. J Clin Invest 97:413-420.
190. Lu, P., Schrag, M.L., Slaughter, D.E., Raab, C.E., Shou, M., Rodrigues, A.D. (2003). Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360.
191. Machinist, J.M., Mayer, M.D., Shet, M.S., Ferrero, J.L., Rodrigues, A.D. (1995). Identifcation of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos 23:1163-1174.
192. Maier, A., Zimmermann, C., Beglinger, C., Drewe, J., Gutmann, H. (2007). Efects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 150:361-368.
193. Maintz, L., Benfadal, S., Allam, J.P., Hagemann, T., Fimmers, R., Novak, N. (2006). Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema. J Allergy Clin Immunol 117:1106-1112.
194. Maintz, L., Novak, N. (2007). Histamine and histamine intolerance. Am J Clin Nutr 85:1185-1196.
195. Malmstrom, K., Schwartz, J., Reiss, T.F., Sullivan, T.J., Reese, J.H., Jauregui, L., et al. (1998). Efect of montelukast on single-dose theophylline pharmacokinetics. Am J Ter 5:189-195.
196. Mamune-Sato, R., Yamauchi, K., Tanno, Y., Ohkawara, Y., Ohtsu, H., Katayose, D., et al. (1992). Functional analysis of alternatively spliced transcripts of the human histidine decarboxylase gene and its expression in human tissues and basophilic leukemia cells. Eur J Biochem 209:533-539.
197. Manchee, G.R., Eddershaw, P.J., Ranshaw, L.E., Herriott, D., Park, G.R., Bayliss, M.K., et al. (1996). Te aliphatic oxidation of salm-eterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 24:555-559.
198. Marnett, L.J., Hurd, H.K., Hollstein, M.C., Levin, D.E., Esterbauer, H., Ames, B.N. (1985). Naturally occurring carbonyl compounds are mutagens in Salmonella tester strain TA104. Mutat Res 148:25-34.
199. Martignoni, M., Monshouwer, M., de Kanter, R., Pezzetta, D., Moscone, A., Grossi, P. (2004). Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey, and human after cryopreservation. Toxicol In Vitro 18:121-128.
200. Martin, P., Riley, R., Back, D.J., Owen, A. (2008). Comparison of the induction profle for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 153:805-819.
201. Martinez, C., Agundez, J.A., Gervasini, G., Martin, R., Benitez, J. (1997). Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7:85-93.
202. Matsushima, S., Maeda, K., Hayashi, H., Debori, Y., Schinkel, A.H., Schuetz, J.D., et al. (2008a). Involvement of multiple efux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483.
203. Matsushima, S., Maeda, K., Inoue, K., Ohta, K.Y., Yuasa, H., Kondo, T., et, al. (2008b). Te inhibition of human multidrug and toxin extrusion 1 (hMATE1) is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 2008 Dec 12. [Epub ahead of print]
204. Mattila, M.J., Kuitunen, T., Plétan, Y. (1992). Lack of pharmacody-namic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 43:179-184.
205. McGinnity, D.F., Berry, A.J., Kenny, J.R., Grime, K., Riley, R.J. (2006). Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 34:1291-1300.
206. Mertens-Talcott, S.U., Zadezensky, I., De Castro, W.V., Derendorf, H., Butterweck, V. (2006). Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 46:1390-1416.
207. Michiels, C., Raes, M., Toussaint, O., Remacle, J. (1994). Importance of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 17:235-248.
208. Milovic, V. (2001). Polyamines in the gut lumen: bioavailability and biodistribution. Eur J Gastroenterol Hepatol 13:1021-1025.
209. Min, D.I., Ku, Y.-.M., Geraets, D.R., Lee, H-C. (1996). Efect of grapefruit juice on the pharmacokinetics and pharmacody-namics of quinidine in healthy volunteers. J Clin Pharmacol 36:469-476.
210. Missbichler, A. (2004). Diagnostischer Nachweis der Aktivität von Diaminooxidase in Serum oder Plasma. (Diagnostic proof of the DAO activity in serum and plasma.) In: Jarisch, R. (Ed.), Histamin-Intoleranz. Histamin, und Seekrankheit. (Histamine Intolerance. Histamine, and Motion Sickness.) (pp 8-17). Stuttgart, Germany: Georg Tieme Verlag KG.
211. Mitchell, J.L., Simkus, C.L., Tane, T.K., Tokarz, P., Bonar, M.M., Frydman, B., et al. (2004). Antizyme induction mediates feedback limitation of the incorporation of specifc polyamine analogues in tissue culture. Biochem J 384:271-279.
212. Mohri, K., Uesawa, Y., Sagawa, K-I. (2000). Efects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metab Dispos 28:482-486.
213. Mondal, G., Chatterjee, U., Samanta, S., Chatterjee, B.P. (2007). Role of pepsin in modifying the allergenicity of bhetki (Lates calcarifer) and mackerel (Rastrelliger kanagurta) fsh. Indian J Biochem Biophs 44:94-100.
214. Moneret-Vautrin, D.A., Kanny, G. (1993). Psedoallergic food reactions. In: Navarro, J., Schmitz, J. (Eds.), Foog allergies (pp 175-189). Paris, France: Doin Ed.
215. Monneret, G., Benoit, Y., Gutowski, M.C., Bienvenu, J. (2000). Detection of basophil activation by fow cytometry in patients with allergy to muscle-relaxant drugs. Anesthesiology 92:275-277.
216. Moore, L.B., Goodwin, B., Jones, S.A., Wisely, G.B., Serabjit-Singh, C.J., Wilson, T.M., et al. (2000). St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
217. Morrow, J.D., Margolies, G.R., Rowland, J., Roberts, L.J. (1991). Evidence that histamine is the causative toxin of scombroid-fsh poisoning. N Engl J Med 324:716-720.
218. Mougey, E.B., Feng, H., Castro, M., Irvin, C.G., Lima, J.J. (2009). Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19:129-138.
219. Mourad, F.H., O'Donnell, L.J.D., Ogutu, E., Dias, J.A., Farthing, MJG. (1995). Role of 5-hydroxytryptamine in intestinal water and electrolyte movement during gut anaphylaxis. Gut 36:553-557.
220. Murray-Stewart, T., Wang, Y., Devereux, W., Casero, R.A. (2002). Cloning and characterization of multiple human polyamine oxidase splice variants that code for isoenzymes with diferent biochemical characteristics. Biochem J 368:673-677.
221. Murray-Stewart, T., Wang, Y., Goodwin, A., Hacker, A., Meeker, A., Casero, R.A. (2008). Nuclear localization of human spermine oxidase isoforms-possible implications in drug response and disease etiology. FEBS J 275:2795-2806.
222. Musial, A., Bajda, M., Malawska, B. (2007). Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. Curr Med Chem 14:2654-2679.
223. Naef, R., Schmid, C., Hofer, M., Minder, S., Speich, R., Boehler, A. (2007). Itraconazole comedication increases systemic levels of inhaled futicasone in lung transplant recipients. Respiration 74:418-422.
224. Nassr, N., Lahu, G., von Richter, O., Reutter, F., Knoerzer, D., Zech, K., et al. (2007). Lack of a pharmacokinetic interaction between steady-state rofumilast and single-dose midazolam in healthy subjects. Br J Clin Pharmacol 63:365-370.
225. Niemi, M. (2007). Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787-802.
226. Nishimura, M., Koeda, A., Shimizu, T., Nakayama, M., Satoh, T., Narimatsu, S., et al. (2008). Comparison of inducibility of sul-fotransferase and UDP-glucuronosyltransferase mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Drug Metab Pharmacokinet 23:45-53.
227. Nishimura, K., Shiina, R., Kashiwagi, K., Igarashi, K. (2006). Decrease in polyamines with aging and their ingestion from food and drink. J Biochem 139:81-90.
228. Nivoix, Y., Levêque, D., Herbrecht, R., Kofel, J.C., Beretz, L., Ubeaud-Sequier, G. (2008). Te enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 47:779-792.
229. Niwa, T., Murayama, N., Yamazaki, H. (2008). Heterotropic coop-erativity in oxidation mediated by cytochrome P450. Curr Drug Metab 9:453-962.
230. Norn, S. (1971). Anaphylactic histamine release and infuence of antirheumatics. Acta Pharmacol Toxicol (Copenh) 30:3-59.
231. Nowack, R. (2008). Cytochrome P450 enzyme, and transport protein-mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's wort-and beyond! Nephrology 13:319-326.
232. O'Reilly, R.A. (1975). Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 83:506-508.
233. Obach, R., Walsky, R.L., Venkatakrishnan, K., Gaman, E.A., Houston, J., Tremaine, L.M. (2006). Te utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmac Exp Ter 316:336-348.
234. Obach, R.S., Walsky, R.L., Venkatakrishnan, K. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
235. Obradovic, T., Dobson, G.G., Shingaki, T., Kungu, T., Hidalgo, I.J. (2007). Assessment of the frst-and second-generation antihis-tamines brain penetration and role of P-glycoprotein. Pharm Res 24:318-327.
236. O'Brien, P.J., Siraki, A.G., Shangari, N. (2005). Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible efects on human health. Crit Rev Toxicol 35:609-662.
237. Ohmori, K., Hasegawa, K., Tamura, T., Miyake, K., Matsubara, M., Masaki, S., et al. (2004). Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 54:809-829.
238. Olinga, P., Elferink, M.G., Draaisma, A.L., Merema, M.T., Castell, J.V., Pérez, G., et al. (2008). Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 33:380-389.
239. Orans, J., Teotico, D.G., Redinbo, M.R. (2005). Te nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 19:2891-2900.
240. Osborne, D., Seidel, E.R. (1990). Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Am J Physiol Gastrointest Liver Physiol 258:G576-G584.
241. O'Sullivan, J., Unzeta, M., Healy, J., O'Sullivan, M.I., Davey, G., Tipton, K.F. (2004). Semicarbazide-sensitive amine oxidases: enzymes with quite a lot to do. Neurotoxicology 25:303-315.
242. Pacifci, G.M., Donatelli, P., Giuliani, L. (1992). Histamine N-methyl transferase: inhibition by drugs. Br J Clin Pharmacol 34:322-327.
243. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., Zeldin, D.C. (2006). Te human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
244. Paiva, T.B., Tominaga, M., Paiva, A.C. (1970). Ionization of histamine, N-acetylhistamine, and their iodinated derivatives. J Med Chem 13:689-692.
245. Patat, A., Ulliac, N., Zieleniuk, I., Stubbs, D., Dunmore, C., Sexton, B., et al. (1995). Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 48:143-150.
246. Pavek, P., Dvorak, Z. (2008). Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab 9:129-143.
247. Pearce, R.E., Leeder, J.S., Kearns, G.L. (2006). Biotransformation of futicasone: in vitro characterization. Drug Metab Dispos 34:1035-1040.
248. Pegg, A.E. (2008). Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator. Am J Physiol Endocrinol Metab 294:E995-E1010.
249. Pelkonen, O., Kapitulnik, J., Gundert-Remy, U., Boobis, A.R., Stockis, A. (2008a). Local kinetics and dynamics of xenobiotics. Crit Rev Toxicol 38:697-720.
250. Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., Raunio, H. (2008b). Inhibition and induction of human cyto-chrome P450 enzymes: current status. Arch Toxicol 82:667-715.
251. Persson, K.P., Ekehed, S., Otter, C., Lutz, E.S., McPheat, J., Masimirembwa, C.M., et al. (2006). Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome P450 induction potential of drugs in vivo in humans. Pharm Res 23:56-69.
252. Petersen, J., Raithel, M., Schwelberger, H.G. (2005). Characterization of functional polymorphisms of the human diamine oxidase gene. Infamm Res 54(Suppl):S69-S70.
253. Peytavin, G., Gautran, C., Otoul, C., Cremieux, A.C., Moulaert, B., Delatour, F., et al. (2005). Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. Eur J Clin Pharmacol 61:267-273.
254. 2-OH-PhIP. Toxicology 166:25-30.
255. Phillips, I.R., Shephard, E.A. (2008). Flavin-containing mono-oxygenases: mutations, disease, and drug response. Trends Pharmacol Sci 29:294-301.
256. Prescott, L.F. (2000). Paracetamol, alcohol, and the liver. Br J Clin Pharmacol 49:291-301.
257. Purcell, W.M., Doyle, K.M., Bagga, L., Derks, M. (1994). Histamine release from mast cells by polyamines: an NMDA receptor-mediated event? Biochem Soc Trans 22:398S.
258. Pustylnyak, V.O., Lebedev, A.N., Gulyaeva, L.F., Lyakhovich, V.V., Slynko, N.M. (2007). Comparative study of CYP2B induction in the liver of rats and mice by diferent compounds. Life Sci 80:324-328.
259. Raaska, K., Niemi, M., Neuvonen, M., Neuvonen, P.J., Kivistö, K.T. (2002). Plasma concentrations of inhaled budesonide and its efects on plasma cortisol are increased by the cyto-chrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ter 72:362-369.
260. Raeissi, S.D., Hidalgo, I.J., Segura-Aguilar, J., Artursson, P. (1999). Interplay between CYP3A-mediated metabolism and polarized efux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16:625-632.
261. Ramaswamy, S.G., Jakoby, W.B. (1987). Amine N-sulfotransferase. J Biol Chem 262:10039-10043.
262. Rasmussen, B.B., Jeppesen, U., Gaist, D., Brøsen, K. (1997). Griseofulvin and fuvoxamine interactions with the metabolism of theophylline. Ter Drug Monit 19:56-62.
263. Rasmussen, B.B., Maënpää, J., Pelkonen, O., Loft, S., Poulsen, H.E., Lykkesfeldt, J., Brøsen, K. (1995). Selective serotonin reuptake inhibitors and theophylline metabolism in human liver micro-somes: potent inhibition by fuvoxamine. Br J Clin Pharmacol 39:151-159.
264. Regunathan, S., Reis, J. (2000). Characterization of arginine decar-boxylase in rat brain and liver: distinction from ornithine decar-boxylase. J Neurochem 74:2201-2208.
265. Reichmuth, D., Lockey, R.F. (2000). Present and potential therapy for allergic rhinitis: a review. BioDrugs 14:371-387.
266. Richard, N., Pivarnik, L., Ellis, P.C., Lee, C. (2008). Efect of matrix on recovery of biogenic amines in fsh. J AOAC Int 91:768-776.
267. Rohatagi, S., Appajosyula, S., Derendorf, H., Szefer, S., Nave, R., Zech, K., et al. (2004). Risk-beneft value of inhaled glucocorti-coids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 44:37-47.
268. Samara, E., Cavanaugh, J.H., Mukherjee, D., Granneman, G.R. (1995). Lack of pharmacokinetic interaction between zileu-ton and phenytoin in humans. Clin Pharmacokinet 29 (Suppl 2):84-91.
269. Sasaki, M., Joh, T. (2007). Oxidative stress and ischemia-reperfusion injury in gastrointestinal tract and antioxidant, protective agents. J Clin Biochem Nutr 40:1-12.
270. Sattler, J., Hafner, D., Klotter, H.J., Lorenz, W., Wagner, P.K. (1988). Food-induced histaminosis as a epidemiological problem: plasma histamine elevation and haemodynamic alterations after oral histamine administration and blockade of diamine oxidase (DAO). Agents Actions 23:361-365.
271. Sattler, J., Hesterberg, R., Lorenz, W., Schmidt, U., Crombach, M., Stahlknecht, C.D. (1985). Inhibition of human and canine diamine oxidase by drugs used in an intensive care unit: relevance for clinical side-efects? Agents Actions 16:91-94.
272. Sattler, J., Lorenz, W., Kubo, K., Schmal, A., Sauer, S., Luben, L. (1989). Food-induced histaminosis under diamine oxidase (DAO) blockade in pigs: further evidence of the key role of elevated plasma histamine levels as demonstrated by successful prophylaxis with antihistamines. Agents Actions 27:212-214.
273. Scandlyn, M.J., Stuart, E.C., Rosengren, R.J. (2008). Sex-specifc differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4:413-424.
274. Schaad, N. (2002). Risks of interaction between drugs, grapefruit juice and red wine. Médecine Hygiène. 2385:665-668.
275. Schleip, T. Cited by Missbichler A. (2004). Online at: www.nutrition-london.net/phdi/p1.nsf/supppages/1012?opendocument&part=4. Accessed 15 January 2009.
276. Schuster, D., Laggner, C., Steindl, T.M., Langer, T. (2006). Development and validation of an in silico P450 profler based on pharma-cophore models. Curr Drug Discov Technol 3:1-48.
277. Schwarz, U.I., Leake, B.F., Kim, R.B., Whomsley, R., Strolin, Benedetti M. (2006). Role of OATP and OAT transporters in levocetirizine cellular uptake. Drug Metab. Rev 38(Suppl 2):239 (No.367).
278. Schweitzer, J.W., Friedhof, A.J., Schwartz, R. (1975). Chocolate, beta-phenethylamine, and migraine re-examined. Nature 257:256.
279. Schwelberger, H.G., Bodner, E. (1997). Purifcation and characterization of diamine oxidase from porcine kidney and intestine. Biochem Biophys Acta 1340:152-164.
280. Schwelberger, H.G. (2004). Diamine oxidase (DAO) enzyme and gene. In: Falus, A. (Ed.), Histamine: Biology and Medical Aspects. (pp 43-52). Budapest, Hungary: SpringMed Publishing.
281. Schwelberger, H.G. (2007). Te origin of mammalian plasma amine oxidases. J Neural Transm 114:757-762.
282. Seiler, N. (2004). Catabolism of polyamines. Amino Acids 26:217-233.
283. Seiler, N., Raul, F. (2007). Polyamines and the intestinal tract. Crit Rev Clin Lab Sci 44:365-411.
284. Seiler, N., Duranton, B., Gosse, F., Raul, F. (2000). Spermine cytotox-icity to human colon carcinoma-derived cells (Caco-2). Cell Biol Toxicol 16:117-130.
285. Sen, N.P. (1969). Analysis and signifcance of tyramine in foods. J Food Sci 34:22-26.
286. Shader, R.I., Granda, B.W., von, Moltke LL, Giancarlo, G.M., Greenblatt, D.J. (1999). Inhibition of human cytochrome P450 isoforms in vitro by zafrlukast. Biopharm Drug Dispos 20:385-388.
287. Shan, L., Vincent, J., Brunzelle, J.S., Dussault, I., Lin, M., Ianculescu, I., et al. (2004). Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol Cell 16:907-917.
288. Sharmin, S., Sakata, K., Kashiwagi, K., Ueda, S., Iwasaki, S., Shirahata, A., et al. (2001). Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem Biophys Res Commun 282:228-235.
289. Sharpe, J.G., Seidel, E.R. (2005). Polyamines are absorbed through a y+ amino acid carrier in rat intestinal epithelial cells. Amino Acids 29:245-253.
290. Shen, S., He, Y., Zeng, S. (2007). Stereoselective regulation of MDR1 expression in Caco-2 cells by cetirizine enantiomers. Chirality 19;485-490.
291. Shiga, T., Hashiguchi, M., Urae, A., Kasanuki, H., Rikihisa, T. (2000). Efect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ter 67:222-228.
292. Shimizu, M., Uno, T., Sugawara, K., Tateishi, T. (2006). Efects of itraco-nazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 61:538-544.
293. Silla Santos, M.H. (1996). Biogenic amines: their importance in foods. Int J Food Microbiol 29:213-231.
294. Simon, L., Szilagyi, G., Bori, Z., Orbay, P., Nagy, Z. (2001). (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia. Eur J Pharmacol 430:235-241.
295. 1-receptor antagonist therapy. Clin Pharmacokin 21:372-393.
296. Sinz, M., Wallace, G., Sahi, J. (2008). Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical predicting induction. AAPS J 10:391-400.
297. Smith, M.J., Garrett, R.H. (2005). A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Infamm Res 54:435-450.
298. Song, B.J., Veech, R.L., Park, S.S., Gelboin, H.V., Gonzalez, F.J. (1989). Induction of rat hepatic N-nitrosodimethylamine demethy-lase by acetone is due to protein stabilization. J Biol Chem 264:3568-3572.
299. Sperber, A.D. (1991). Toxic interaction between fuvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 6:460-462.
300. Squires, E.J., Sueyoshi, T., Negishi, M. (2004). Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J Biol Chem 279:49307-49314.
301. St Germain, R.M., Yigit, S., Wells, L., Girotto, J.E., Salazar, J.C. (2007). Cushing's syndrome and severe adrenal suppression caused by futicasone and protease inhibitor combination in an HIV-infected adolescent. AIDS Patient Care STDS 21:373-377.
302. Steen, D. (2004). Immortalized human hepatocytes: a new advance in convenience and performance. Curr Separat 20:137-140.
303. Stein, C.M. (2002). Are herbal products dietary supplements or drugs? An important question for public safety. Clin Pharmacol Ter 71:411-413.
304. Steinhof, M., Grifts, C., Church, M., Lugar, T.A. (2004). Histamine. In: Burns, T., Breathnach, S., Cox, N., Grifths, C. (Eds.), Rook's Textbook of Dermatology (pp 50-52). Oxford, United Kingdom: Blackwell Science.
305. Strolin Benedetti, M., Tipton, K., Whomsley, R. (2007). Amine oxi-dases and mono-oxygenases in the in vivo metabolism of xeno-biotic amines in humans: has the involvment of amine oxidases been neglected? Fund Clin Pharmacol 21:467-479.
306. Strolin Benedetti, M., Boucher, T., Carlsson, A., Fowler, C.J. (1983). Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat. Biochem Pharmacol 32:47-52.
307. Sugimura, T. (2000). Nutrition and dietary carcinogens. Carcinogenesis 21:387-395.
308. Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J.Y., Repa, J.J., et al. (2004). Te nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. Mol Cell 16:893-905.
309. 1-receptor antagonists, pro-methazine, and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ter Drug Monit 25:192-196.
310. Szöko, E., Tábi, T., Borbás, T., Dalmadi, B., Tihanyi, K., Magyar, K. (2004). Assessment of the N-oxidation of deprenyl, metham-phetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis 25:2866-2875.
311. Tada, Y., Tsuda, Y., Otsuka, T., Nagasawa, K., Kimura, H., Kusaba, T., et al. (1992). Case report: nifedipine-rifampicin interaction attenuates the efect on blood pressure in a patient with essential hypertension. Am J Med Sci 303:25-27.
312. Tahara, H., Kusuhara, H., Maeda, K., Koepsell, H., Fuse, E., Sugiyama, Y. (2006). Inhibition of OAT3 mediated renal uptake as a mechanism for drug-drug interaction between foxofenadine and probenecid. Drug Metab Dispos 34:743-747.
313. Takagi, S., Nakajima, M., Mohri, T., Yokoi, T. (2008). Post-transcriptional regulation of human pregnane X receptor by micro-RNA afects the expression of cytochrome P450 3A4. J Biol Chem 283:9674-9680.
314. Tanel, A., Averill-Bates, D.A. (2007). Activation of the death receptor pathway of apoptosis by the aldehyde acrolein. Free Radic Biol Med 42:798-810.
315. Tang, W., Wang, R.W., Lu, A.Y. (2005). Utility of recombinant cyto-chrome P450 enzymes: a drug metabolism perspective. Curr Drug Metab 6:503-517.
316. Tarlo, S.M., Sussman, G.L. (1993). Asthma and anaphylactoid reactions to food additives. Can Fam Physician 39:1119-1123.
317. Tarrus, E., Cami, J., Roberts, D.J., Spickett, R.G., Celdran, E., Segura, J. (1987). Accumulation of cafeine in healthy volunteers treated with furafylline. Br J Clin Pharmacol 23:9-18.
318. Ten Eick, A.P., Blumer, J.L., Reed, M.D. (2001). Safety of antihista-mines in children. Drug Saf 24:119-147.
319. Tomas, T., Tomas, T.J. (2001). Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58:244-258.
320. Tompson, C.M., Capdevila, J.H., Strobel, H.W. (2000). Recombinant cytochrome P450 2D18 metabolism of dopamine and arachi-donic acid. J Pharmacol Exp Ter 294:1120-1130.
321. Timsit, Y.E., Negishi, M. (2007). CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231-246.
322. Tipton, K.F., Boyce, S., O'Sullivan, J., Davey, G.P., Healy, J. (2004). Monoamine oxidases: certainties and uncertainties. Curr Med Chem 11:1965-1982.
323. Tolonen, A., Turpeinen, M., Pelkonen, O. (in press). Liquid chroma-tography-mass spectrometry in in vitro drug metabolite screening. Drug Discov Today
324. Toninello, A., Pietrangeli, P., De Marchi, U., Salvi, M., Mondovi, B. (2006). Amine oxidases in apoptosis and cancer. Biochim. Biophys Acta 1765:1-13.
325. Trackman, P.C., Kagan, H.M. (1979). Nonpeptidyl amine inhibitors are substrates of lysyl oxidase. J Biol Chem 254:7831-7836.
326. Tsuruoka, S., Ioka, T., Wakaumi, M., Sakamoto, K., Ookami, H., Fujimura, A. (2006). Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insuf-fciency: frst case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ter 79:389-396.
327. Erratum in: Clin Pharmacol Ter 80:645.
328. Tunc, T., Oter, S., Güven, A., Topal, T., Kul, M., Korkmaz, A., et al. (2008). Protective efect of sulfhydryl-containing antioxidants against ischemia/reperfusion injury of prepubertal rat intestine. J Gastroenterol Hepatol Dec 1. [Epub ahead of print]
329. Ucar, G., Topaloglu, E., Burak Kandilci, H., Gumusel, B. (2005). Elevated semicarbazide-sensitive amine oxidase (SSAO) activity in lung with ischemia-reperfusion injury: protective efect of ischemic preconditioning plus SSAO inhibition. Life Sci 78: 421-427.
330. Uemura, T., Yerushalmi, H.F., Tsaprailis, G., Stringer, D.E., Pastorian, K.E., Hawel, L. (2008) Identifcation and characterization of a diamine exporter in colon epithelial cells. J Biol Chem 283:26428-26435.
331. Ulwelling, W. (1985). "Pseudo-allergy": treatment with an MAO inhibitor. Psychosomatics 26:535-536.
332. Usmani, O.S., Ito, K., Maneechotesuwan, K., Ito, M., Johnson, M., Barnes, P.J., et al. (2005). Glucocorticoid receptor nuclear trans-location in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 172:704-712.
333. van Berkel, W.J., Kamerbeek, N.M., Fraaije, M.W. (2006). Flavoprotein mono-oxygenases, a diverse class of oxidative biocatalysts. J Biotechnol 124:670-689.
334. van den Berg, G.A., Kingma, A.W., Elzinga, H., Muskiet, F.A. (1986). Determination of N-(3-acetamidopropyl)pyrrolidin-2-one, a metabolite of spermidine, in urine by isotope dilution mass fragmentography. J Chromatogr 383:251-258.
335. van den Brekel, A.M., Harrington, L. (1994). Toxic efects of theophyl-line caused by fuvoxamine. Can Med Assoc J 151:1289-1290.
336. Van Hecken, A., Depré, M., Verbesselt, R., Wynants, K., De Lepeleire, I., Arnout, J., et al. (1999). Efect of montelukast on the pharma-cokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 39:495-500.
337. Varis, T., Kaukonen, K.M., Kivistö, K.T., Neuvonen, P.J. (1998). Plasma concentrations and efects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ter 64:363-368.
338. Varis, T., Kivistö, K.T., Backman, J.T., Neuvonen, P.J. (2000). Te
339. Vermeir, M., Annaert, P., Mamidi, R.N., Roymans, D., Meuldermans, W., Mannens, G. (2005). Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin Drug Metab Toxicol 1:75-90.
340. Vizcaino, S., Caballero, M.J., Carrillo, J.A., Benitez, J. (2003). Efects of grapefruit juice on ebastine metabolism. Methods and fndings in experimental and clinical pharmacology. 25 (Suppl A):170.
341. von Richter, O., Lahu, G., Huennemeyer, A., Herzog, R., Zech, K., Hermann, R. (2007). Efect of fuvoxamine on the pharmacokinetics of rofumilast and rofumilast N-oxide. Clin Pharmacokinet 46:613-622.
342. Vujcic, S., Diegelman, P., Bacchi, C.J., Kramer, D.L., Porter, C.W. (2002). Identifcation and characterization of a novel favin-containing spermine oxidase of mammalian cell origin. Biochem J 367:665-675.
343. Wallace, H.M., Fraser, A.V., Hughes, A. (2003). A perspective of polyamine metabolism. Biochem J 376:1-14.
344. Walsky, R.L., Boldt, S.E. (2008). In vitro cytochrome P450 inhibition and induction. Curr Drug Metab 9:928-939.
345. Walsky, R.L., Obach, R.S., Gaman, E.A., Gleeson, J.P., Proctor, W.R. (2005). Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418.
346. Walubo, A., Barr, S., Abraham, A.M., Coetsee, C. (2004). Te role of cytochrome-P450 inhibitors in the prevention of hepato-toxicity after paracetamol overdose in rats. Hum Exp Toxicol 23:49-54.
347. Wang, E.J., Casciano, C.N., Clement, R.P., Johnson, W.W. (2001). Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 29:1080-1083.
348. Wang, Y., Casero, R.A. (2006). Mammalian polyamine catabolism: a therapeutic target, a pathological problem, or both? J Biochem 139:17-25.
349. Wang, Z., Hamman, M.A., Huang, S-M., Lesko, L.J., Hall, S.D. (2002). Efect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ter 71:414-420.
350. Wantke, F., Hemmer, W., Haglmuller, T., Gotz, M., Jarish, R. (1996). Histamine in wine. Bronchoconstriction after a double-blind, placebo-controlled red wine provocation test. Int Arch Allergy Immunol 110:397-400.
351. Wantke, F., Gotz, M., Jarisch, R. (1994). Te red wine provocation test: intolerance to histamine as a model of food intolerance. Allergy Proc 15:27-32.
352. Watanabe, T., Taguchi, Y., Maeyama, K., Wada, H. (1991). Formation of histamine: histidine decarboxylase. In: Uvnäs, B. (Ed.), Histamine and Histamine Antagonists (pp. 145-163). Berlin, Germany: Springer-Verlag.
353. Weaver, R., Graham, K.S., Beattie, I.G., Riley, R.J. (2003). Cytochrome P450 inhibition using recombinant proteins and mass spec-trometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966.
354. Weber, W.W. (1997). Pharmacogenetics. New York/Oxford: Oxford University Press.
355. Westerink, W.M., Schoonen, W.G. (2007). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepa-tocytes and their induction in HepG2 cells. Toxicol In Vitro 21:1581-1591.
356. 1 antihistamines: the importance of pharmacokinetics in the evaluation of safe and therapeutically efective agents. Curr Med Chem Anti-infamm Antiallergy Agents 4:451-464.
357. Whomsley, R., Strolin-Benedetti, M., Baltes, E. (2006). Comment on severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufciency. Clin Pharmacol Ter 80:715-716
358. Wienkers, L.C., Heath, T.J. (2005). Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4:825-1433
359. Wilson, F.E. (1981). Acute respiratory failure secondary to polymyx-in-B inhalation. Chest 79:237-239.
360. Wood, P.L., Khan, M.A., Moskal, J.R., Todd, K.G., Tanay, V.A., Baker, G. (2007). Te concept of "aldehyde load" in neurodegenera-tive mechanisms: cytotoxicity of the polyamine degradation products hydrogen peroxide, acrolein, 3-aminopropanal, 3-acetamidopropanal, and 4-aminobutanal in a retinal ganglion cell line. Brain Res 1145:150-156.
361. Worland, P.J., Ilett, K.F. (1983). Intestinal contribution to the presys-temic elimination of beta-phenethylamine in the rat. J Pharm Pharmacol 35:636-640.
362. Wütrich, B. (1988). [Acetylsalicylic acid pseudoallergy: an anomaly of thrombocyte function?]. Hautarzt 39:631-634.
363. Xu, R.X., Lambert, M.H., Wisely, B.B., Warren, E.N., Weinert, E.E., Waitt, G.M., et al. (2004). A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer. Mol Cell 16:919-928.
364. Yao, C., Kunze, K.L., Kharasch, E.D., Wang, Y., Trager, W.F., Ragueneau, I., et al. (2001). Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ter 70:415-424.
365. Yap, Y.G., Camm, A.J. (1999). Arrhythmogenic mechanisms of nonse-dating antihistamines. Clin Exp Allergy 29(Suppl 3):174-181.
366. Yasui-Furukori, N., Uno, T., Sugawara, K., Tateishi, T. (2005). Diferent efects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinet-ics. Clin Pharmacol Ter 77:17-23.
367. Yatsunami, K., Ohtsu, H., Tsuchikawa, M., Higuchi, T., Ishibashi, K., Shida, A., et al. (1994). Structure of the L-histidine decarboxy-lase gene. J Biol Chem 269:1554-1559.
368. Yu, A.M., Granvil, C.P., Haining, R.L., Krausz, K.W., Corchero, J., Küpfer, A., et al. (2003). Te relative contribution of monoam-ine oxidase and cytochrome P450 isozymes to the metabolic deamination of the trace amine tryptamine. J Pharmacol Exp Ter 304:539-546.
369. Yu, Z., Li, W., Hillman, J., Brunk, U.T. (2004). Human neuroblastoma (SH-SY5Y) cells are highly sensitive to the lysosomotropic aldehyde 3-aminopropanal. Brain Res 1016:163-169.
370. Yueh, M.F., Kawahara, M., Raucy, J. (2005). High-volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 33:38-48.
371. Zangar, R.C., Davydov, D.R., Verma, S. (2004). Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol Appl Pharmacol 199:316-331.
372. Zhang, F., Xiong, D.H., Wang, W., Shen, H., Xiao, P., Yang, F., et al. (2006). HDC gene polymorphisms are associated with age at natural menopause in Caucasian women. Biochem Biophys Res Commun 348:1378-1382.
373. Zhang, Z.Y., Wong, Y.N. (2005). Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 6:241-257.
374. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., et al. (2005). Mechanism-based inhibition of cyto-chrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304.
375. Zhu, Z., Kim, S., Chen, T., Lin, J.H., Bell, A., Bryson, J., et al. (2004). Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen 9:533-540.
376. Zimatkin, S.M., Anichtchik, O.V. (1999). Alcohol-histamine interactions. Alcohol 34:141-147.